Abstracts tagged "Cutaneous"

Abstract Number: 0365 • ACR Convergence 2022
Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus (CLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part B)
Victoria Werth¹, Ronald van Vollenhoven², Richard Furie³, Filippa Nyberg⁴, Kenneth Kalunian⁵, Sandra Navarra⁶, Juanita Romero-Diaz⁷, Wenbin Zhu⁸, Catherine Barbey⁹, Cristina Musselli⁸ and Nathalie Franchimont⁸, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Northwell Health, Great Neck, NY, ⁴Karolinska University Hospital, Stockholm, Sweden, ⁵University of California San Diego, La Jolla, CA, ⁶University of Santo Tomas, Manila, Philippines, ⁷Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁸Biogen, Cambridge, MA, ⁹Biogen, Baar, Switzerland
Background/Purpose: BIIB059 is a humanized monoclonal antibody against BDCA2, a receptor exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of cutaneous…
Abstract Number: 0556 • ACR Convergence 2022
Immune Checkpoint VISTA Regulates Type I Interferon (IFN-I) Production and Controls UV Light Triggered Skin IFN-I Response
Zachary Peters¹, Lindsay Mendyka¹, Sicong Shan¹, Angelique Cortez¹, William Rigby², Christopher Burns¹, Randolph Noelle³ and Sladjana Skopelja-Gardner¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth Hitchcock Medical Center, Lebanon, PA, ³Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Most lupus patients chronically exhibit higher IFN-I scores in the skin, peripheral blood, and kidneys that is exacerbated by ultraviolet (UV) light. In normal…
Abstract Number: 0661 • ACR Convergence 2022
Cutaneous Type I IFN Responses in Systemic Lupus Erythematosus Are Associated with Inflammatory Phenotype and Altered Wound Healing Function of Lupus Fibroblasts from Non-Lesional Skin
Lisa Abernathy-Close, Suzanne Shoffner-Beck, Annie Lu, Amanda Victory, Amy Hurst, Craig Dobry, Rachael Wasikowski, Johann Gudjonsson, Alex Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogenous, disfiguring, and difficult-to-treat manifestation of systemic lupus erythematosus (SLE) with scar formation in CLE subtypes such as…
Abstract Number: 0974 • ACR Convergence 2022
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
Lucy Marie Carter¹, Zoe Wigston¹, Jack Arnold¹ and Philip Laws², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Cutaneous lupus eyrthematosus (CLE) is frequently refractory to immunosuppressive therapies including B-cell depletion, but response varies by morphology with the chronic discoid (DLE) subtype…
Abstract Number: 0979 • ACR Convergence 2022
Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
Susan Manzi¹, Jorge Sanchez-Guerrero², Naoto Yokogawa³, Joerg Wenzel⁴, Josephine C. Ocran-Appiah⁵, Munther Khamashta⁶, Julia H N Harris⁷, Bernie Rubin⁸, Norma Lynn Fox⁹, Roger A Levy¹⁰ and Victoria Werth¹¹, ¹Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²University of Toronto, Division of Rheumatology, Department of Medicine Mount Sinai Hospital/University Health Network, Toronto, ON, Canada, ³Tokyo Metropolitan Tama Medical Center, Department of Rheumatic Diseases, Tokyo, Japan, ⁴University Hospital of Bonn, Department of Dermatology and Allergy, Bonn, Germany, ⁵GlaxoSmithKline, Clinical Science Immunology, Rockville, MD, ⁶GlaxoSmithKline, Medical Affairs, Dubai, United Arab Emirates, ⁷GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁸GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁹GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA, ¹⁰GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ¹¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Background/Purpose: Mucocutaneous manifestations affect >80% of patients (pts) with SLE and can contribute to their poor quality of life through unwanted attention, self-consciousness, emotional symptoms,…
Abstract Number: 0970 • ACR Convergence 2021
Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes
Grace Hile¹, Patrick Coit², Bin Xu¹, Shannon Estadt¹, Jacob Martens³, Rachael Wasikowski¹, Lam Tsoi¹, Ramiro Iglesias-Bartolome⁴, Celine Berthier¹, Allison Billi⁵, Johann Gudjonsson⁵, Amr Sawalha² and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh, Pittsburgh, PA, ³Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁴NIH, National Cancer Institute, Bethesda, MD, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation and photosensitivity are common manifestations of cutaneous (CLE) and systemic lupus erythematosus (SLE), yet the mechanisms underlying heightened cell death and epidermal…
Abstract Number: 1043 • ACR Convergence 2021
Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study
Mehmet Hocaoglu¹, Mark Davis², Maria Valenzuela-Almada³, Jesse Dabit², Shirley-Ann Osei-Onomah², Sebastian Vallejo-Ramos², Tina Gunderson², Kurt Greenlund⁴, Kamil Barbour⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia², ¹University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Centers for Disease Control, Atlanta, GA, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Cutaneous lupus erythematosus (CLE) patients report impaired quality of life due to cutaneous and psychological morbidity. Previous literature on the prevalence of comorbidities in…
Abstract Number: 1282 • ACR Convergence 2021
Classification of Disease Activity and Damage in Cutaneous Lupus
Laila Abbas, Karabi Nandy and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Cutaneous Lupus Disease Area and Severity Index (CLASI) can quantify disease activity and damage in Cutaneous Lupus Erythematosus (CLE). Classification of CLASI scores…
Abstract Number: 1491 • ACR Convergence 2021
Single-cell Analysis of Paired Skin and Blood Samples from Patients with SLE and Cutaneous Lupus Suggests CD16+ DCs Arise from Non-classical Monocytes That Enter Nonlesional Skin, Undergo Type I IFN Education, and Engage in Extensive Crosstalk with Diverse Immune and Stromal Cell Types
Allison Billi¹, Feiyang Ma², Olesya Plazyo³, Grace Hile³, Xianying Xing³, Mehrnaz Gharaee-Kermani⁴, Rachael Wasikowski³, Lam Tsoi³, Matteo Pellegrini², Robert L. Modlin², Johann Gudjonsson¹ and J. Michelle Kahlenberg³, ¹Department of Dermatology, University of Michigan, Ann Arbor, MI, ²University of California Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Internal Medicine - Division of Rheumatology and Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an incompletely understood autoimmune disease that can occur in isolation or in the context of SLE. CLE is often…
Abstract Number: 1495 • ACR Convergence 2021
Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials
Thomas Vazquez¹, Jay Patel², Daisy Yan³, Emily Keyes⁴, DeAnna Diaz⁵, Yubin Li⁶, Madison Grinnell⁶, Rui Feng⁷ and Victoria Werth³, ¹FIU Wertheim College of Medicine, Virginia Beach, VA, ²Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, ⁷University of Pennsylvania Department of Biostatistics, Philadelphia, PA
Background/Purpose: Lupus erythematous (LE) is a systemic autoimmune disease with a variety of cutaneous manifestations. Antimalarials are first-line systemic therapy, yet not all patients respond…
Abstract Number: 0598 • ACR Convergence 2021
Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study
Adrienne Joseph, Brandon Windsor, Linda Hynan and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Epidemiological studies have shown that discoid lupus erythematosus (DLE) has a higher incidence and prevalence in minorities, particularly Black individuals. Racial differences in clinical…
Abstract Number: 0278 • ACR Convergence 2020
Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study
Mehmet Hocaoglu¹, Mark Denis P. Davis², Shirley-Ann Osei-Onomah³, Jesse Dabit², Rachel Giblon², Thomas O'Byrne², Cynthia Crowson⁴ and Ali Duarte-Garcia², ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous chronic disease with potential for long lasting morbidity. Studies that provide incidence data on the entire spectrum…
Abstract Number: 0300 • ACR Convergence 2020
Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
Sirisha Sirobhushanam¹, Allison Billi², Alex Tsoi², Celine Berthier², Johann Gudjonsson³ and J. Michelle Kahlenberg⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann ArborUniversity of Michigan, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Lupus lesional skin has elevated interferon expression, is highly colonized with Staphylococcus aureus (50%) and has no FDA-approved treatment options. S. aureus is known…
Abstract Number: 0985 • ACR Convergence 2020
Early and Sustained Reduction in Severity of Skin Disease with Anifrolumab Treatment in Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): Pooled Data from 2 Phase 3 Studies
Victoria Werth¹, Richard Furie², Eric Morand³, J. Michelle Kahlenberg⁴, Rubana Kalyani⁵, Gabriel Abreu⁶, Lilia Pineda⁵ and Raj Tummala⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, ³Monash University, Melbourne, Australia, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Up to 85% of patients with SLE experience skin disease.1 The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated index…
Abstract Number: 0986 • ACR Convergence 2020
BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
Victoria Werth¹, Richard Furie², Juanita Romero-Díaz³, Sandra Navarra⁴, Kenneth Kalunian⁵, Ronald van Vollenhoven⁶, Filippa Nyberg⁷, Benjamin Kaffenberger⁸, Saira Sheikh⁹, Goran Radunovic¹⁰, Xiaobi Huang¹¹, Hua Carroll¹², Francois Gaudreault¹², Adam Meyers¹¹, Catherine Barbey¹³, Cristina Musselli¹¹ and Nathalie Franchimont¹¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴University of Santo Tomas, Manila, Philippines, ⁵University of California San Diego, La Jolla, CA, ⁶Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁷Karolinska University Hospital, Stockholm, Sweden, ⁸Ohio State University, Columbus, OH, ⁹Division of Rheumatology, Allergy and Immunology, University of North Carolina, Chapel Hill, NC, ¹⁰Institute of Rheumatology, University of Belgrade, Belgrade, Serbia, ¹¹Biogen, Cambridge, MA, ¹²Biogen, Cambridge, ¹³Biogen, Baar, Switzerland
Background/Purpose: No approved targeted therapies have been developed for cutaneous lupus erythematosus (CLE), a disfiguring autoimmune disease that severely impairs quality of life.1 BIIB059 is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].